February 2020, Vol 11, No 1 | Payers’ Perspectives In Oncology | Including ASH 2019 Highlights

Novel BCMA-Directed CAR T-Cell Therapy Had Excellent Responses in Heavily Pretreated Patients with Multiple Myeloma

FEATURING:

Hematologic Malignancies, Multiple Myeloma, Personalized Medicine

Investigational Oral Form of Azacitidine Improves Survival as Maintenance Therapy in Patients with Acute Myeloid Leukemia

FEATURING:

Leukemia, Personalized Medicine

First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL

FEATURING:

Leukemia, Personalized Medicine

Zanubrutinib, Next-Generation BTK, Leads to Impressive Responses in Patients with CLL or SLL

FEATURING:

Leukemia, Personalized Medicine

Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome

FEATURING:

Emerging Therapies

Xtandi Now Approved for Metastatic Castration-Sensitive Prostate Cancer

FDA Approvals, News & Updates

Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation

FDA Approvals, News & Updates

Keytruda Indicated for BCG-Unresponsive High-Risk, Non–Muscle Invasive Bladder Cancer

FDA Approvals, News & Updates

Enhertu, a Dual-Targeted Therapy, Approved for Metastatic HER2-Positive Breast Cancer

FDA Approvals, News & Updates

Page 1 of 3

1
2
3